Brief: Sciclone Pharmaceuticals Says China's Nmpa Approved Co's Investigational New Drug Application
19/03/2023 22:46
March 20 (Reuters) - SciClone Pharmaceuticals (Holdings)
Ltd 6600.HK :
* CHINA'S NMPA HAS OFFICIALLY APPROVED CO'S INVESTIGATIONAL
NEW
DRUG APPLICATION FOR VABOREM
Further company coverage: 6600.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SciClone Pharmaceuticals (Holdings)
See all newsOneRobotics surges on plan to buy more shares
Brief: Onerobotics (Shenzhen) To Procure Affiliate Of Co To Acquire 59.9% Stake Of Nanoleaf Limited, Others
Brief: OneRobotics (Shenzhen) Says Final Offer Price Under Global Offering Is HK$73.80 Per H Share
Brief: Sciclone Pharmaceuticals (Holdings) Announces Proposal For Privatisation Of Co By Silver Pegasus Investment
Brief: SciClone Pharmaceuticals Says Trading In Shares Halted